Skip to main content Skip to footer
Alopexx
  • Home
  • About
    • Overview
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Antimicrobial Resistance
  • Therapeutic Solutions
    • Overview
    • Immune Therapy for Microbial Diseases
    • PNAG Platform
    • Posters & Publications
  • Pipeline
    • Overview
    • Monoclonal Antibody F598
    • Vaccine AV0328
    • Potential of Targeting PNAG
  • News
  • Contact

News

Oct 20, 2021 8:30am EDT

Alopexx Expands Leadership Team with Appointment of Thomas T. Thomas as Chief Financial Officer

rss_feed News RSS
© Alopexx. All Rights Reserved.
Privacy Policy Disclaimer Sitemap